|
|
||||||||
CORRECTION |
On page 55 of the article titled "B-Type Natriuretic Peptide: A Diagnostic, Prognostic, and Therapeutic Tool in Heart Failure" (Am J Crit Care. 2004;13:4655), an error appeared in the CE test, question 9. It should have read as follows:
9. Which of the following is the recommended dose of nesiritide (Natrecor), as a therapeutic agent for use in heart failure, after an initial intravenous bolus?
The entire CE test is reprinted on page 171 of this issue of the Journal.
| ||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |